Literature DB >> 22869370

A novel mechanism for antibody-based anthrax toxin neutralization: inhibition of prepore-to-pore conversion.

Adva Mechaly1, Haim Levy, Eyal Epstein, Ronit Rosenfeld, Hadar Marcus, Einat Ben-Arie, Avigdor Shafferman, Arie Ordentlich, Ohad Mazor.   

Abstract

Protective antigen (PA), a key component of anthrax toxin, mediates the entry of lethal factor (LF) or edema factor (EF) through a membranal pore into target cells. We have previously reported the isolation and chimerization of cAb29, an anti-PA monoclonal antibody that effectively neutralizes anthrax toxin in an unknown mechanism. The aim of this study was to elucidate the neutralizing mechanism of this antibody in vitro and to test its ability to confer post-exposure protection against anthrax in vivo. By systematic evaluation of the steps taking place during the PA-based intoxication process, we found that cAb29 did not interfere with the initial steps of intoxication, namely its ability to bind to the anthrax receptor, the consecutive proteolytic cleavage to PA(63), oligomerization, prepore formation, or LF binding. However, the binding of cAb29 to the prepore prevented its pH-triggered transition to the transmembranal pore, thus preventing the last step of intoxication, i.e. the translocation of LF/EF into the cell. Epitope mapping, using a phage display peptide library, revealed that cAb29 binds the 2α(1) loop in domain 2 of PA, a loop that undergoes major conformational changes during pore formation. In vivo, we found that 100% of anthrax-infected rabbits survived when treated with cAb29 12 h after exposure. In conclusion, these experiments demonstrate that cAb29 exerts its potent neutralizing activity in a unique manner by blocking the prepore-to-pore conversion process.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22869370      PMCID: PMC3463365          DOI: 10.1074/jbc.M112.400473

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation.

Authors:  D Borden Lacy; Darran J Wigelsworth; Roman A Melnyk; Stephen C Harrison; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

2.  Real-time monitoring of morphological changes in living cells by electronic cell sensor arrays: an approach to study G protein-coupled receptors.

Authors:  Naichen Yu; Josephine M Atienza; Jerome Bernard; Sebastien Blanc; Jenny Zhu; Xiaobo Wang; Xiao Xu; Yama A Abassi
Journal:  Anal Chem       Date:  2006-01-01       Impact factor: 6.986

Review 3.  Anthrax toxin: receptor binding, internalization, pore formation, and translocation.

Authors:  John A T Young; R John Collier
Journal:  Annu Rev Biochem       Date:  2007       Impact factor: 23.643

4.  Crystal structure of the anthrax toxin protective antigen.

Authors:  C Petosa; R J Collier; K R Klimpel; S H Leppla; R C Liddington
Journal:  Nature       Date:  1997-02-27       Impact factor: 49.962

5.  Anthrax protective antigen: prepore-to-pore conversion.

Authors:  C J Miller; J L Elliott; R J Collier
Journal:  Biochemistry       Date:  1999-08-10       Impact factor: 3.162

6.  A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo.

Authors:  Y Singh; V K Chaudhary; S H Leppla
Journal:  J Biol Chem       Date:  1989-11-15       Impact factor: 5.157

7.  Crystal structure of a complex between anthrax toxin and its host cell receptor.

Authors:  Eugenio Santelli; Laurie A Bankston; Stephen H Leppla; Robert C Liddington
Journal:  Nature       Date:  2004-07-04       Impact factor: 49.962

8.  Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis.

Authors:  Vladimir A Karginov; Tanisha M Robinson; Jenny Riemenschneider; Basil Golding; Michael Kennedy; Joseph Shiloach; Ken Alibek
Journal:  FEMS Immunol Med Microbiol       Date:  2004-01-15

Review 9.  Vaccines: countering anthrax: vaccines and immunoglobulins.

Authors:  John D Grabenstein
Journal:  Clin Infect Dis       Date:  2008-01-01       Impact factor: 9.079

10.  Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax.

Authors:  Mark T Albrecht; Han Li; E Diane Williamson; Chris S LeButt; Helen C Flick-Smith; Conrad P Quinn; Hans Westra; Darrell Galloway; Alfred Mateczun; Stanley Goldman; Herman Groen; Les W J Baillie
Journal:  Infect Immun       Date:  2007-07-23       Impact factor: 3.441

View more
  10 in total

1.  A neutralizing antibody that blocks delivery of the enzymatic cargo of Clostridium difficile toxin TcdB into host cells.

Authors:  Heather K Kroh; Ramyavardhanee Chandrasekaran; Zhifen Zhang; Kim Rosenthal; Rob Woods; Xiaofang Jin; Andrew C Nyborg; G Jonah Rainey; Paul Warrener; Roman A Melnyk; Benjamin W Spiller; D Borden Lacy
Journal:  J Biol Chem       Date:  2017-11-27       Impact factor: 5.157

2.  Revisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for Anthrax.

Authors:  Itai Glinert; Elad Bar-David; Assa Sittner; Shay Weiss; Josef Schlomovitz; Amir Ben-Shmuel; Adva Mechaly; Zeev Altboum; David Kobiler; Haim Levy
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 3.  Designing inhibitors of anthrax toxin.

Authors:  Ekaterina M Nestorovich; Sergey M Bezrukov
Journal:  Expert Opin Drug Discov       Date:  2014-01-22       Impact factor: 6.098

Review 4.  An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Authors:  Lernik Ohanjanian; Kenneth E Remy; Yan Li; Xizhong Cui; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2015-04-28       Impact factor: 6.206

5.  Combination of two candidate subunit vaccine antigens elicits protective immunity to ricin and anthrax toxin in mice.

Authors:  David J Vance; Yinghui Rong; Robert N Brey; Nicholas J Mantis
Journal:  Vaccine       Date:  2014-12-02       Impact factor: 3.641

Review 6.  Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs.

Authors:  Eran Diamant; Amram Torgeman; Eyal Ozeri; Ran Zichel
Journal:  Toxins (Basel)       Date:  2015-05-29       Impact factor: 4.546

7.  Different mechanisms of two anti-anthrax protective antigen antibodies and function comparison between them.

Authors:  Siping Xiong; Tingting Zhou; Feng Zheng; Xudong Liang; Yongping Cao; Chunhui Wang; Zhengqin Feng; Qi Tang; Jin Zhu
Journal:  BMC Infect Dis       Date:  2019-11-07       Impact factor: 3.090

Review 8.  Exotoxin-Targeted Drug Modalities as Antibiotic Alternatives.

Authors:  Moona Sakari; Arttu Laisi; Arto T Pulliainen
Journal:  ACS Infect Dis       Date:  2022-01-31       Impact factor: 5.084

9.  Isolation of Anti-Ricin Protective Antibodies Exhibiting High Affinity from Immunized Non-Human Primates.

Authors:  Tal Noy-Porat; Ronit Rosenfeld; Naomi Ariel; Eyal Epstein; Ron Alcalay; Anat Zvi; Chanoch Kronman; Arie Ordentlich; Ohad Mazor
Journal:  Toxins (Basel)       Date:  2016-03-03       Impact factor: 4.546

10.  Binding of the von Willebrand Factor A Domain of Capillary Morphogenesis Protein 2 to Anthrax Protective Antigen Vaccine Reduces Immunogenicity in Mice.

Authors:  Fabiana Freire Mendes de Oliveira; Sireesha Mamillapalli; Srinivas Gonti; Robert N Brey; Han Li; Jarad Schiffer; Arturo Casadevall; James G Bann
Journal:  mSphere       Date:  2020-01-15       Impact factor: 4.389

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.